{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T08:14:41Z","timestamp":1768464881234,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00277-023-05605-8","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T03:01:42Z","timestamp":1704769302000},"page":"1643-1653","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunotyping of peripheral blood lymphocytes by flow cytometry reveals Th cell as a potential prognostic biomarker for extranodal NK\/T-cell lymphoma"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4853-2845","authenticated-orcid":false,"given":"Fei","family":"Qi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuce","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningjing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"issue":"9","key":"5605_CR1","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1038\/s41375-021-01313-2","volume":"35","author":"H Wang","year":"2021","unstructured":"Wang H, Fu BB, Gale RP, Liang Y (2021) NK-\/T-cell lymphomas. Leukemia 35(9):2460\u20132468. https:\/\/doi.org\/10.1038\/s41375-021-01313-2","journal-title":"Leukemia"},{"issue":"1","key":"5605_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13045-022-01293-5","volume":"15","author":"E Tse","year":"2022","unstructured":"Tse E, Zhao WL, Xiong J, Kwong YL (2022) How we treat NK\/T-cell lymphomas. J Hematol Oncol 15(1):74. https:\/\/doi.org\/10.1186\/s13045-022-01293-5","journal-title":"J Hematol Oncol"},{"issue":"25","key":"5605_CR3","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D, International TCLP (2008) International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26(25):4124\u20134130. https:\/\/doi.org\/10.1200\/JCO.2008.16.4558","journal-title":"J Clin Oncol"},{"issue":"6","key":"5605_CR4","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1016\/S2352-3026(20)30103-4","volume":"7","author":"L Wang","year":"2020","unstructured":"Wang L, Wang JW (2020) Extranodal natural-killer T-cell lymphoma: experience from China. Lancet Haematol 7(6):e441. https:\/\/doi.org\/10.1016\/S2352-3026(20)30103-4","journal-title":"Lancet Haematol"},{"issue":"2","key":"5605_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s12185-008-0021-7","volume":"87","author":"K Aozasa","year":"2008","unstructured":"Aozasa K, Takakuwa T, Hongyo T, Yang WI (2008) Nasal NK\/T-cell lymphoma: epidemiology and pathogenesis. Int J Hematol 87(2):110\u2013117. https:\/\/doi.org\/10.1007\/s12185-008-0021-7","journal-title":"Int J Hematol"},{"issue":"23","key":"5605_CR6","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1182\/blood-2017-12-791418","volume":"131","author":"M Yamaguchi","year":"2018","unstructured":"Yamaguchi M, Suzuki R, Oguchi M (2018) Advances in the treatment of extranodal NK\/T-cell lymphoma, nasal type. Blood 131(23):2528\u20132540. https:\/\/doi.org\/10.1182\/blood-2017-12-791418","journal-title":"Blood"},{"issue":"13","key":"5605_CR7","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1182\/bloodadvances.2020001852","volume":"4","author":"SN Qi","year":"2020","unstructured":"Qi SN, Yang Y, Song YQ, Wang Y, He X, Hu C et al (2020) First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK\/T-cell lymphoma: a retrospective analysis from the CLCG. Blood Adv 4(13):3141\u20133153. https:\/\/doi.org\/10.1182\/bloodadvances.2020001852","journal-title":"Blood Adv"},{"issue":"4","key":"5605_CR8","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1016\/S2352-3026(19)30283-2","volume":"7","author":"CP Fox","year":"2020","unstructured":"Fox CP, Civallero M, Ko YH, Manni M, Skrypets T, Pileri S et al (2020) Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. Lancet Haematol 7(4):e284\u2013ee94. https:\/\/doi.org\/10.1016\/S2352-3026(19)30283-2","journal-title":"Lancet Haematol"},{"issue":"1","key":"5605_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1200\/JCO.2016.68.1619","volume":"35","author":"M Yamaguchi","year":"2017","unstructured":"Yamaguchi M, Suzuki R, Oguchi M, Asano N, Amaki J, Akiba T et al (2017) Treatments and outcomes of patients with extranodal natural killer\/t-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan. J Clin Oncol 35(1):32\u201339. https:\/\/doi.org\/10.1200\/JCO.2016.68.1619","journal-title":"J Clin Oncol"},{"issue":"1","key":"5605_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/cam4.569","volume":"5","author":"L Zhang","year":"2016","unstructured":"Zhang L, Jiang M, Xie L, Zhang H, Jiang Y, Yang QP et al (2016) Five-year analysis from phase 2 trial of \u201csandwich\u201d chemoradiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer\/T-cell lymphoma. Cancer Med 5(1):33\u201340. https:\/\/doi.org\/10.1002\/cam4.569","journal-title":"Cancer Med"},{"issue":"2","key":"5605_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s12185-015-1809-x","volume":"102","author":"H Ding","year":"2015","unstructured":"Ding H, Chang J, Liu LG, Hu D, Zhang WH, Yan Y et al (2015) High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed\/refractory extranodal natural killer\/T cell lymphoma: a retrospective study. Int J Hematol 102(2):181\u2013187. https:\/\/doi.org\/10.1007\/s12185-015-1809-x","journal-title":"Int J Hematol"},{"issue":"6","key":"5605_CR12","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","volume":"117","author":"A Jaccard","year":"2011","unstructured":"Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F et al (2011) Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study. Blood 117(6):1834\u20131839. https:\/\/doi.org\/10.1182\/blood-2010-09-307454","journal-title":"Blood"},{"issue":"1","key":"5605_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","volume":"11","author":"X Li","year":"2018","unstructured":"Li X, Cheng Y, Zhang M, Yan J, Li L, Fu X et al (2018) Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma. J Hematol Oncol 11(1):15. https:\/\/doi.org\/10.1186\/s13045-018-0559-7","journal-title":"J Hematol Oncol"},{"issue":"1","key":"5605_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1186\/s12885-017-3501-4","volume":"17","author":"J Lai","year":"2017","unstructured":"Lai J, Xu P, Jiang X, Zhou S, Liu A (2017) Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer\/T-cell lymphoma patient with multi-line resistance: a case report. BMC Cancer 17(1):507. https:\/\/doi.org\/10.1186\/s12885-017-3501-4","journal-title":"BMC Cancer"},{"key":"5605_CR15","doi-asserted-by":"publisher","first-page":"608304","DOI":"10.3389\/fonc.2020.608304","volume":"10","author":"Z Yan","year":"2020","unstructured":"Yan Z, Yao S, Liu Y, Zhang J, Li P, Wang H et al (2020) Durable response to sintilimab and chidamide in a patient with pegaspargase- and immunotherapy-resistant NK\/T-cell lymphoma: case report and literature review. Front Oncol 10:608304. https:\/\/doi.org\/10.3389\/fonc.2020.608304","journal-title":"Front Oncol"},{"issue":"17","key":"5605_CR16","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","volume":"129","author":"YL Kwong","year":"2017","unstructured":"Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B et al (2017) PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase. Blood 129(17):2437\u20132442. https:\/\/doi.org\/10.1182\/blood-2016-12-756841","journal-title":"Blood"},{"issue":"1","key":"5605_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-021-00768-0","volume":"6","author":"R Tao","year":"2021","unstructured":"Tao R, Fan L, Song Y, Hu Y, Zhang W, Wang Y et al (2021) Sintilimab for relapsed\/refractory extranodal NK\/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4). Signal Transduct Target Ther 6(1):365. https:\/\/doi.org\/10.1038\/s41392-021-00768-0","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"5605_CR18","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00428-016-2011-0","volume":"469","author":"WY Kim","year":"2016","unstructured":"Kim WY, Jung HY, Nam SJ, Kim TM, Heo DS, Kim CW et al (2016) Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK\/T cell lymphoma is associated with better prognosis. Virchows Arch 469(5):581\u2013590. https:\/\/doi.org\/10.1007\/s00428-016-2011-0","journal-title":"Virchows Arch"},{"issue":"4","key":"5605_CR19","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41379-019-0392-8","volume":"33","author":"J Cho","year":"2020","unstructured":"Cho J, Kim SJ, Park WY, Kim J, Woo J, Kim G et al (2020) Immune subtyping of extranodal NK\/T-cell lymphoma: a new biomarker and an immune shift during disease progression. Mod Pathol 33(4):603\u2013615. https:\/\/doi.org\/10.1038\/s41379-019-0392-8","journal-title":"Mod Pathol"},{"issue":"1","key":"5605_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.imlet.2006.10.009","volume":"108","author":"KS Blum","year":"2007","unstructured":"Blum KS, Pabst R (2007) Lymphocyte numbers and subsets in the human blood. Do they mirror the situation in all organs? Immunol Lett 108(1):45\u201351. https:\/\/doi.org\/10.1016\/j.imlet.2006.10.009","journal-title":"Immunol Lett"},{"issue":"4","key":"5605_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jcma.2012.12.003","volume":"76","author":"MH Hung","year":"2013","unstructured":"Hung MH, Yu YB, Hsiao LT, Hong YC, Liu JH, Gau JP et al (2013) Absolute lymphocyte count predicts response to rituximab-containing salvage treatment for relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma with prior rituximab exposure. J Chin Med Assoc 76(4):195\u2013200. https:\/\/doi.org\/10.1016\/j.jcma.2012.12.003","journal-title":"J Chin Med Assoc"},{"issue":"10","key":"5605_CR22","doi-asserted-by":"publisher","first-page":"10938","DOI":"10.21037\/apm-21-2551","volume":"10","author":"C Li","year":"2021","unstructured":"Li C, Li W, Xu G, You M, Wu W, Kuang L (2021) Relationship between the absolute lymphocyte count\/absolute monocyte count ratio, soluble interleukin 2 receptor level, serum programmed cell death 1 level, and the prognosis of patients with diffuse large B-cell lymphoma. Ann. Palliat Med 10(10):10938\u201310945. https:\/\/doi.org\/10.21037\/apm-21-2551","journal-title":"Palliat Med"},{"issue":"9","key":"5605_CR23","doi-asserted-by":"publisher","first-page":"e606","DOI":"10.1016\/j.clml.2020.03.007","volume":"20","author":"A Mohsen","year":"2020","unstructured":"Mohsen A, Taalab M, Abousamra N, Mabed M (2020) Prognostic significance of absolute lymphocyte count, absolute monocyte count, and absolute lymphocyte count to absolute monocyte count ratio in follicular non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 20(9):e606\u2013ee15. https:\/\/doi.org\/10.1016\/j.clml.2020.03.007","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"5605_CR24","doi-asserted-by":"publisher","first-page":"E241","DOI":"10.1002\/ajh.26561","volume":"97","author":"R Bansal","year":"2022","unstructured":"Bansal R, Novo M, Al Saleh AS, Guerrico AG, Zhang H, Shao Z et al (2022) Peak absolute lymphocyte count after CAR-T infusion predicts clinical response in aggressive lymphoma. Am J Hematol 97(7):E241\u2013E2E4. https:\/\/doi.org\/10.1002\/ajh.26561","journal-title":"Am J Hematol"},{"issue":"2","key":"5605_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12185-021-03148-0","volume":"114","author":"S Rai","year":"2021","unstructured":"Rai S, Inoue H, Hanamoto H, Matsuda M, Maeda Y, Wada Y et al (2021) Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial. Int J Hematol 114(2):205\u2013216. https:\/\/doi.org\/10.1007\/s12185-021-03148-0","journal-title":"Int J Hematol"},{"issue":"1","key":"5605_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/annonc\/mdq314","volume":"22","author":"JJ Huang","year":"2011","unstructured":"Huang JJ, Jiang WQ, Lin TY, Huang Y, Xu RH, Huang HQ et al (2011) Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer\/T-cell lymphoma, nasal type. Ann Oncol 22(1):149\u2013155. https:\/\/doi.org\/10.1093\/annonc\/mdq314","journal-title":"Ann Oncol"},{"issue":"2","key":"5605_CR27","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1080\/10428194.2020.1834090","volume":"62","author":"L Hamdi","year":"2021","unstructured":"Hamdi L, Creidy R, Boudjemaa S, Hendel-Chavez H, Hugues P, Taoufik Y et al (2021) Frequent altered distribution of peripheral B-lymphocyte subsets in pediatric and adolescent patients with classical Hodgkin lymphoma. Leuk Lymphoma 62(2):300\u2013307. https:\/\/doi.org\/10.1080\/10428194.2020.1834090","journal-title":"Leuk Lymphoma"},{"key":"5605_CR28","unstructured":"Lin J, Chen X, Wu H, Chen X, Hu X, Xu J (2021) Peripheral blood lymphocyte counts in patients with infectious mononucleosis or chronic active Epstein-Barr virus infection and prognostic risk factors of chronic active Epstein-Barr virus infection. Am J Transl Res 13(11):12797\u201312806. eCollection"},{"issue":"14","key":"5605_CR29","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors P","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors P (1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 329(14):987\u2013994. https:\/\/doi.org\/10.1056\/NEJM199309303291402","journal-title":"N Engl J Med"},{"issue":"7","key":"5605_CR30","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/leu.2015.44","volume":"29","author":"Y Yang","year":"2015","unstructured":"Yang Y, Zhang YJ, Zhu Y, Cao JZ, Yuan ZY, Xu LM et al (2015) Prognostic nomogram for overall survival in previously untreated patients with extranodal NK\/T-cell lymphoma, nasal-type: a multicenter study. Leukemia 29(7):1571\u20131577. https:\/\/doi.org\/10.1038\/leu.2015.44","journal-title":"Leukemia"},{"issue":"4","key":"5605_CR31","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1200\/JCO.2005.04.1384","volume":"24","author":"J Lee","year":"2006","unstructured":"Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH et al (2006) Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 24(4):612\u2013618. https:\/\/doi.org\/10.1200\/JCO.2005.04.1384","journal-title":"J Clin Oncol"},{"issue":"3","key":"5605_CR32","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","volume":"17","author":"SJ Kim","year":"2016","unstructured":"Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H et al (2016) A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol 17(3):389\u2013400. https:\/\/doi.org\/10.1016\/S1470-2045(15)00533-1","journal-title":"Lancet Oncol"},{"issue":"4","key":"5605_CR33","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1159\/000510912","volume":"144","author":"HJ Shin","year":"2021","unstructured":"Shin HJ, Kim DY, Chung J, Shin KH, Lee H (2021) Prognostic impact of peripheral blood T-cell subsets at the time of diagnosis on survival in patients with diffuse large B-cell lymphoma. Acta Haematol 144(4):427\u2013437. https:\/\/doi.org\/10.1159\/000510912","journal-title":"Acta Haematol"},{"issue":"2","key":"5605_CR34","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.semcancer.2012.01.004","volume":"22","author":"CW Dawson","year":"2012","unstructured":"Dawson CW, Port RJ, Young LS (2012) The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol 22(2):144\u2013153. https:\/\/doi.org\/10.1016\/j.semcancer.2012.01.004","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"5605_CR35","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1136\/jclinpath-2020-207048","volume":"75","author":"FE Laddaga","year":"2022","unstructured":"Laddaga FE, Ingravallo G, Mestice A, Tamma R, Perrone T, Maiorano E et al (2022) Correlation between circulating blood and microenvironment T lymphocytes in diffuse large B-cell lymphomas. J Clin Pathol 75(7):493\u2013497. https:\/\/doi.org\/10.1136\/jclinpath-2020-207048","journal-title":"J Clin Pathol"},{"issue":"12","key":"5605_CR36","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1038\/sj.leu.2404819","volume":"21","author":"LF Porrata","year":"2007","unstructured":"Porrata LF, Ristow K, Witzig TE, Tuinistra N, Habermann TM, Inwards DJ et al (2007) Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas. Leukemia 21(12):2554\u20132556. https:\/\/doi.org\/10.1038\/sj.leu.2404819","journal-title":"Leukemia"},{"issue":"4","key":"5605_CR37","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.1038\/bcj.2017.37","volume":"7","author":"Y Kusano","year":"2017","unstructured":"Kusano Y, Yokoyama M, Terui Y, Nishimura N, Mishima Y, Ueda K et al (2017) Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma. Blood Cancer J 7(4):e558. https:\/\/doi.org\/10.1038\/bcj.2017.37","journal-title":"Blood Cancer J"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05605-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05605-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05605-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T06:02:56Z","timestamp":1712901776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05605-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["5605"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05605-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]},"assertion":[{"value":"14 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}